Four companies that are settled in Shanghai (Nanxiang) Precision Medicine Industrial Park were listed on the "2022 China Biomedical Industry Value List", exemplifying the potential and strength of the industrial park.

The list is known as a panorama of domestic medical and health investment, an important reference for getting to know excellent biomedical companies, and a close-up look into the prospects of the industry.

Shanghai (Nanxiang) Precision Medicine Industrial Park. [Photo/WeChat account: sh-jiading]

Established in January 2017, Shanghai (Nanxiang) Precision Medicine Industrial Park has introduced more than 270 companies in relative fields with over 300 high-level talents from home and abroad.

The industrial park is an industrialization platform developed by the Jiading district government and Fudan University to explore effective business modes for transfering scientific and technological achievements, said Wang Rui, director of the innovative service center.

The industrial park's most distinctive supportive service is the integration of resources in investment and financing, which can provide start-ups with more financing opportunities, Wang said.

In addition, the industrial park has formed long-term cooperation with professional healthcare institutions, such as the 18 affiliated hospitals of Fudan University, to offer clinical resources matchmakings, clinical trials, testing and other professional services, Wang added.

By 2023, the industrial park aims to cultivate 15 municipal-level sci-tech "little giants", incubate 20 companies above designated size in the biomedical field, build five international professional platforms, and maintain the annual growth rate of 10 percent for the number of biomedical patent applications.